AccuraGen

AccuraGen, founded in 2014 and based in Foster City, California, is a private diagnostics company pioneering next-generation liquid biopsy technology. Its core innovation is a rolling-circle amplification platform that achieves exceptional sensitivity and specificity by correcting sequencing errors through concatemer consensus, positioning it to address key applications in therapy selection, minimal residual disease monitoring, and early cancer detection. The company operates with a multidisciplinary team and a partnership-driven model to advance its assays from technical development through clinical validation and commercialization.

Proprietary rolling-circle amplification (RCA) for consensus-based concatemer error correction, enabling ultra-sensitive and specific detection of genetic alterations in cell-free DNA for liquid biopsy applications.

AccuraGen competes in a crowded and well-funded liquid biopsy market dominated by companies like Guardant Health and Exact Sciences, as well as large diagnostic conglomerates. Its differentiation hinges on demonstrating superior analytical sensitivity and specificity through its unique error-correction technology to capture share in the most technically demanding application segments.